Cargando…
Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis
The Korean government decided to schedule heterologous vaccinations on dialysis patients for early achievement of immunization against Coronavirus disease 2019(COVID-19). However, the effects of heterologous immunizations in hemodialysis (HD) patients are unclear. One hundred (HD) patients from Gang...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207316/ https://www.ncbi.nlm.nih.gov/pubmed/35734170 http://dx.doi.org/10.3389/fimmu.2022.894700 |
_version_ | 1784729500115795968 |
---|---|
author | Kim, Dae Kyu Jung, Su Woong Moon, Ju-Young Jeong, Kyung Hwan Hwang, Hyeon Seok Kim, Jin Sug Lee, Sang-Ho Kang, So-Young Kim, Yang Gyun |
author_facet | Kim, Dae Kyu Jung, Su Woong Moon, Ju-Young Jeong, Kyung Hwan Hwang, Hyeon Seok Kim, Jin Sug Lee, Sang-Ho Kang, So-Young Kim, Yang Gyun |
author_sort | Kim, Dae Kyu |
collection | PubMed |
description | The Korean government decided to schedule heterologous vaccinations on dialysis patients for early achievement of immunization against Coronavirus disease 2019(COVID-19). However, the effects of heterologous immunizations in hemodialysis (HD) patients are unclear. One hundred (HD) patients from Gangdong Kyung Hee University Hospital and Kyung Hee Medical Center and 100 hospital workers from Gangdong Kyung Hee University Hospital were enrolled in this study. The HD patients received the mixing schedule of ChAdOx1/BNT162b2 vaccinations at 10-week intervals, while hospital workers received two doses of ChAdOx1 vaccines at 12-week intervals. Serum IgG to a receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2 was measured 1 month after the first dose, 2 months and 4 months after the second dose. The median [interquartile range] anti-RBD IgG was 82.1[34.5, 176.6] AU/ml in HD patients and 197.1[124.0, 346.0] AU/ml in hospital workers (P < 0.001) after the first dose. The percentage of positive responses (IgG > 50 AU/ml) was 65.0% and 96.0% among the both group, respectively (P < 0.001). The anti-RBD IgG levels increased significantly by 2528.8 [1327.6, 5795.1] AU/ml with a 100.0% positive response rate in HD patients 2 months after the second dose, which was higher than those in hospital workers 981.4[581.5, 1891.4] AU/ml (P < 0.001). Moreover, anti-RBD IgG remains constantly high, and positive response remains 100% in HD patients 4 months after the second dose. This study suggests that heterologous vaccinations with ChAdOx1/BNT162b2 can be an alternative solution on HD patients for early and strong induction of humoral response. |
format | Online Article Text |
id | pubmed-9207316 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92073162022-06-21 Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis Kim, Dae Kyu Jung, Su Woong Moon, Ju-Young Jeong, Kyung Hwan Hwang, Hyeon Seok Kim, Jin Sug Lee, Sang-Ho Kang, So-Young Kim, Yang Gyun Front Immunol Immunology The Korean government decided to schedule heterologous vaccinations on dialysis patients for early achievement of immunization against Coronavirus disease 2019(COVID-19). However, the effects of heterologous immunizations in hemodialysis (HD) patients are unclear. One hundred (HD) patients from Gangdong Kyung Hee University Hospital and Kyung Hee Medical Center and 100 hospital workers from Gangdong Kyung Hee University Hospital were enrolled in this study. The HD patients received the mixing schedule of ChAdOx1/BNT162b2 vaccinations at 10-week intervals, while hospital workers received two doses of ChAdOx1 vaccines at 12-week intervals. Serum IgG to a receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2 was measured 1 month after the first dose, 2 months and 4 months after the second dose. The median [interquartile range] anti-RBD IgG was 82.1[34.5, 176.6] AU/ml in HD patients and 197.1[124.0, 346.0] AU/ml in hospital workers (P < 0.001) after the first dose. The percentage of positive responses (IgG > 50 AU/ml) was 65.0% and 96.0% among the both group, respectively (P < 0.001). The anti-RBD IgG levels increased significantly by 2528.8 [1327.6, 5795.1] AU/ml with a 100.0% positive response rate in HD patients 2 months after the second dose, which was higher than those in hospital workers 981.4[581.5, 1891.4] AU/ml (P < 0.001). Moreover, anti-RBD IgG remains constantly high, and positive response remains 100% in HD patients 4 months after the second dose. This study suggests that heterologous vaccinations with ChAdOx1/BNT162b2 can be an alternative solution on HD patients for early and strong induction of humoral response. Frontiers Media S.A. 2022-06-06 /pmc/articles/PMC9207316/ /pubmed/35734170 http://dx.doi.org/10.3389/fimmu.2022.894700 Text en Copyright © 2022 Kim, Jung, Moon, Jeong, Hwang, Kim, Lee, Kang and Kim https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Kim, Dae Kyu Jung, Su Woong Moon, Ju-Young Jeong, Kyung Hwan Hwang, Hyeon Seok Kim, Jin Sug Lee, Sang-Ho Kang, So-Young Kim, Yang Gyun Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis |
title | Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis |
title_full | Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis |
title_fullStr | Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis |
title_full_unstemmed | Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis |
title_short | Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response After Heterologous Immunizations With ChAdOx1/BNT162b2 in End-Stage Renal Disease Patients on Hemodialysis |
title_sort | severe acute respiratory syndrome coronavirus 2 antibody response after heterologous immunizations with chadox1/bnt162b2 in end-stage renal disease patients on hemodialysis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207316/ https://www.ncbi.nlm.nih.gov/pubmed/35734170 http://dx.doi.org/10.3389/fimmu.2022.894700 |
work_keys_str_mv | AT kimdaekyu severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis AT jungsuwoong severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis AT moonjuyoung severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis AT jeongkyunghwan severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis AT hwanghyeonseok severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis AT kimjinsug severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis AT leesangho severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis AT kangsoyoung severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis AT kimyanggyun severeacuterespiratorysyndromecoronavirus2antibodyresponseafterheterologousimmunizationswithchadox1bnt162b2inendstagerenaldiseasepatientsonhemodialysis |